Skip to Content
Merck
  • Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure.

Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure.

Pharmacotherapy (2014-08-29)
Robert J DiDomenico, Adam P Bress, Kwanta Na-Thalang, Yvonne Y Tsao, Vicki L Groo, Kelly L Deyo, Shitalben R Patel, Jeffrey R Bishop, Jerry L Bauman
ABSTRACT

To compare the frequency of achieving a therapeutic serum digoxin concentration (SDC), defined as 0.5-0.9 ng/ml, by using a simplified nomogram to individualize digoxin dosing with standard dosing practices in patients with heart failure, and to characterize the relationship between genetic polymorphisms of the ABCB1 gene and SDC. Prospective study with a historical control group. Outpatient care center of an urban academic medical center. A total of 131 adults with heart failure due to left ventricular dysfunction who were treated with digoxin. Digoxin doses were determined either by the dosing nomogram (65 patients) or standard care (SC; 66 patients) by using historical controls who were randomly selected from a list of SDCs obtained from laboratory records and who had their digoxin doses determined by standard dosing practices. The primary end point was the proportion of patients achieving a steady-state SDC of 0.5-0.9 ng/ml; secondary end points were mean SDC and proportion of patients achieving a steady-state SDC lower than 1.0 ng/ml. Postdistributive steady-state SDCs were measured 2-4 weeks after digoxin dosage adjustment or initiation. Therapeutic SDCs were achieved with similar frequency in both groups (38.7% in the nomogram group vs 34.5% in the SC group, p=0.65); however, more patients in the nomogram group had SDCs lower than 1.0 ng/ml than in the SC group (85.0% vs 44.9%, p<0.001). Mean daily digoxin doses were lower in the nomogram group (149 ± 67 μg vs 177 ± 74 μg, p=0.02), resulting in lower mean SDCs compared with those in the SC group (0.52 ± 0.30 ng/ml vs 1.12 ± 0.58 ng/ml, p<0.001). Patients in the pharmacogenetic substudy provided blood samples for genotyping of three common ABCB1 single nucleotide polymorphisms: C1236T (rs1128503), G2677T/A (rs2032582), and C3435T (rs1045642). SDCs were not significantly associated with ABCB1 genotypes. Our simplified digoxin dosing nomogram resulted in lower SDCs compared with standard dosing practices but achieved therapeutic SDCs with similar frequency. A greater proportion of patients dosed according to our nomogram had SDCs lower than 1.0 ng/ml, consistent with consensus guidelines. Genetic polymorphisms of the ABCB1 gene were not associated with SDC.

MATERIALS
Product Number
Brand
Product Description

Supelco
Digoxin, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
SKU
Pack Size
Availability
Price
Quantity
Supelco
Digoxin, analytical standard
SKU
Pack Size
Availability
Price
Quantity
USP
Digoxin, United States Pharmacopeia (USP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity
Digoxin, European Pharmacopoeia (EP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity
Digoxin for peak identification, European Pharmacopoeia (EP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity